Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bgc-20-1531 Free Base SCHEMBL29433722 | 1.00 | PTGER4 (1.00) | PTGER4 | |
| SCHEMBL3534655 | 0.90 | PTGER4 (1.00) | PTGER4 | |
| SCHEMBL3532327 | 0.89 | PTGER4 (0.81) | PTGER4 | |
| SCHEMBL3541275 | 0.86 | PTGER4 (0.80) | PTGER4 | |
| Bgc-20-1531 Free Base SCHEMBL29508262 | 0.84 | PTGER4 (1.00) | PTGER4 | |
| SCHEMBL4688621 | 0.84 | PTGER4 (1.00) | PTGER4 | |
| Bgc-20-1531 Free Base SCHEMBL30114901 | 0.84 | PTGER4 (1.00) | PTGER4 | |
| Bgc-20-1531 Free Base SCHEMBL2355810 | 0.84 | PTGER4 (1.00) | PTGER4 | |
| SCHEMBL4689376 | 0.83 | PTGER4 (0.87) | PTGER4 | |
| SCHEMBL14271689 | 0.81 | PTGER4 (0.71) | PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160317514-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC. (JP) | 2016-11-03 | — | — | US | claimed |
| EP-2976105-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | AskAt Inc. (JP) | 2016-01-27 | — | — | EP | claimed |
| EP-2555774-B1 | Medicine combinations containing pde4 inhibitors and ep4 receptor antagonists | BOEHRINGER INGELHEIM INT (DE) | 2015-10-21 | — | — | EP | claimed |
| US-8877758-B2 | Combinations of medicaments, containing PDE4-inhibitors and EP4-receptor-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | claimed |
| WO-2014148053-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC. (JP) | 2014-09-25 | — | — | WO | claimed |
| US-20130237527-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-12 | — | — | US | claimed |
| US-20130225609-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-29 | — | — | US | claimed |
| EP-2555773-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4 INHIBITORS AND EP4 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2013-02-13 | — | — | EP | claimed |
| EP-2555774-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4 INHIBITORS AND EP4 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2013-02-13 | — | — | EP | claimed |
| EP-2538978-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RaQualia Pharma Inc (JP) | 2013-01-02 | — | — | EP | claimed |
| US-20120316197-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RAQUALIA PHARMA INC. (JP) | 2012-12-13 | — | — | US | claimed |
| WO-2011124524-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4 INHIBITORS AND EP4 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-13 | — | — | WO | claimed |
| WO-2011124525-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4 INHIBITORS AND EP4 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-13 | — | — | WO | claimed |
| WO-2011102149-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RAQUALIA PHARMA INC. (JP) | 2011-08-25 | — | — | WO | claimed |
| US-7858644-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2010-12-28 | — | — | US | claimed |
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2009-06-04 | — | — | US | claimed |
| US-7507754-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-03-24 | — | — | US | claimed |
| EP-1603893-B1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2008-05-21 | — | — | EP | claimed |
| US-20080039502-A1 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-02-14 | — | — | US | claimed |
| US-20230165859-A1 | N-SUBSTITUTED INDOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-01 | — | — | US | disclosed |
| EP-2976105-B1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC (JP) | 2023-01-04 | — | — | EP | disclosed |
| EP-3625224-B1 | N-SUBSTITUTED INDOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-08-04 | — | — | EP | disclosed |
| US-10786490-B2 | Use of EP4 receptor antagonists in the treatment of cartilage disease | ASKAT INC. (JP) | 2020-09-29 | — | — | US | disclosed |
| US-10786490-B2 | Use of EP4 receptor antagonists in the treatment of cartilage disease | ASKAT INC. (JP) | 2020-09-29 | — | — | US | disclosed |
| US-10745411-B2 | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-08-18 | — | — | US | disclosed |
| EP-3625224-A1 | N-SUBSTITUTED INDOLE DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2020-03-25 | — | — | EP | disclosed |
| US-20200069686-A1 | N-SUBSTITUTED INDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2020-03-05 | — | — | US | disclosed |
| US-20200048278-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INT (DE) | 2020-02-13 | — | — | US | disclosed |
| CN-110621666-A | N-substituted indole derivatives | 爱杜西亚药品有限公司 | 2019-12-27 | — | — | CN | disclosed |
| US-10391086-B2 | Use of EP4 receptor antagonists in the treatment of cartilage disease | ASKAT INC. (JP) | 2019-08-27 | — | — | US | disclosed |
| US-10391086-B2 | Use of EP4 receptor antagonists in the treatment of cartilage disease | ASKAT INC. (JP) | 2019-08-27 | — | — | US | disclosed |
| WO-2018210995-A1 | N-SUBSTITUTED INDOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | disclosed |
| US-20180193324-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC. (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180193324-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC. (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180193324-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC. (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180072754-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INT (DE) | 2018-03-15 | — | — | US | disclosed |
| US-20170360764-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC. (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20170360764-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC. (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20170360764-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC. (JP) | 2017-12-21 | — | — | US | disclosed |
| US-9802954-B2 | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-20170008903-A9 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-01-12 | — | — | US | disclosed |
| US-20160317514-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC. (JP) | 2016-11-03 | — | — | US | disclosed |
| US-20160317514-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC. (JP) | 2016-11-03 | — | — | US | disclosed |
| US-20160317514-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC. (JP) | 2016-11-03 | — | — | US | disclosed |
| US-9457084-B2 | Use of EP4 receptor antagonists in the treatment of IL-23 mediated diseases | RAQUALIA PHARMA INC. (JP) | 2016-10-04 | — | — | US | disclosed |
| US-9457084-B2 | Use of EP4 receptor antagonists in the treatment of IL-23 mediated diseases | RAQUALIA PHARMA INC. (JP) | 2016-10-04 | — | — | US | disclosed |
| US-9457084-B2 | Use of EP4 receptor antagonists in the treatment of IL-23 mediated diseases | RAQUALIA PHARMA INC. (JP) | 2016-10-04 | — | — | US | disclosed |
| EP-2538978-B1 | USE OF AN EP4 RECEPTOR ANTAGONIST IN THE TREATMENT OF ALLERGIC CONTACT DERMATITIS AND PSORIASIS | RAQUALIA PHARMA INC (JP) | 2016-09-07 | — | — | EP | disclosed |
| EP-2976105-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | AskAt Inc. (JP) | 2016-01-27 | — | — | EP | disclosed |
| EP-2748156-B1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INT (DE) | 2015-12-16 | — | — | EP | disclosed |
| EP-2555774-B1 | Medicine combinations containing pde4 inhibitors and ep4 receptor antagonists | BOEHRINGER INGELHEIM INT (DE) | 2015-10-21 | — | — | EP | disclosed |
| US-9150586-B2 | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| US-20150148322-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-28 | — | — | US | disclosed |
| US-20150045376-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-12 | — | — | US | disclosed |
| US-20140350035-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR- ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
| US-8877758-B2 | Combinations of medicaments, containing PDE4-inhibitors and EP4-receptor-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| WO-2014148053-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC. (JP) | 2014-09-25 | — | — | WO | disclosed |
| EP-2748156-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | Boehringer Ingelheim International GmbH (DE) | 2014-07-02 | — | — | EP | disclosed |
| US-8609670-B2 | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-17 | — | — | US | disclosed |
| US-20130237527-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-12 | — | — | US | disclosed |
| US-20130225609-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130079359-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-28 | — | — | US | disclosed |
| WO-2013026797-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-28 | — | — | WO | disclosed |
| EP-2555773-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4 INHIBITORS AND EP4 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2013-02-13 | — | — | EP | disclosed |
| EP-2555774-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4 INHIBITORS AND EP4 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2013-02-13 | — | — | EP | disclosed |
| EP-2538978-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RaQualia Pharma Inc (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20120316197-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RAQUALIA PHARMA INC. (JP) | 2012-12-13 | — | — | US | disclosed |
| US-20120316197-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RAQUALIA PHARMA INC. (JP) | 2012-12-13 | — | — | US | disclosed |
| US-20120316197-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RAQUALIA PHARMA INC. (JP) | 2012-12-13 | — | — | US | disclosed |
| WO-2011124524-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4 INHIBITORS AND EP4 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011124525-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4 INHIBITORS AND EP4 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011102149-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RAQUALIA PHARMA INC. (JP) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011102149-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RAQUALIA PHARMA INC. (JP) | 2011-08-25 | — | — | WO | disclosed |
| US-7858644-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-7858644-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-7858644-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
| US-7528157-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-7507754-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-03-24 | — | — | US | disclosed |
| US-7507754-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-03-24 | — | — | US | disclosed |
| US-7507754-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-03-24 | — | — | US | disclosed |
| EP-1603893-B1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2008-05-21 | — | — | EP | disclosed |
| EP-1603893-B1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2008-05-21 | — | — | EP | disclosed |
| US-20080039502-A1 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| US-20080039502-A1 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| US-20080039502-A1 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| US-20070123575-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK ACQUISITION LIMITED (GB) | 2007-05-31 | — | — | US | disclosed |
| US-20070123575-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK ACQUISITION LIMITED (GB) | 2007-05-31 | — | — | US | disclosed |
| US-20070123575-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK ACQUISITION LIMITED (GB) | 2007-05-31 | — | — | US | disclosed |
| US-7196089-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
| US-7196089-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
| US-7196089-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
| EP-1603893-A1 | EP4 RECEPTOR ANTAGONISTS | Pharmagene Laboratories Ltd (GB) | 2005-12-14 | — | — | EP | disclosed |
| US-20040192767-A1 | EP4 receptor antagonists | ASTERAND UK ACQUISITION LIMITED (GB) | 2004-09-30 | — | — | US | disclosed |
| WO-2004067524-A1 | EP4 RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2004-08-12 | — | — | WO | disclosed |
| WO-2004067524-A1 | EP4 RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (22 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048278-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | CBS, CYSLTR1, DHPS | PTGER4 192/4885 |
| US-20230165859-A1 | N-SUBSTITUTED INDOLE DERIVATIVES | PTGER2, PTGER1, PTGDR2 | PTGER4 7/4885 |
| US-20140350035-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR- ANTAGONISTS | PTGER4, PTGER1, PDE4A | PTGER4 1/4885 |
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | PTGER4, NR4A1, NR4A2 | PTGER4 1/4885 |
| US-10391086-B2 | Use of EP4 receptor antagonists in the treatment of cartilage disease | PTGER4, PTGER1, EPB41 | PTGER4 1/4885 |
| US-20180072754-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | CBS, CYSLTR1, DHPS | PTGER4 192/4885 |
| US-10745411-B2 | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma | CBS, DHPS, TPMT | PTGER4 260/4885 |
| US-10786490-B2 | Use of EP4 receptor antagonists in the treatment of cartilage disease | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885 |
| US-20130079359-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | CBS, SQOR, TST | PTGER4 306/4885 |
| US-20120316197-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | PTGER4, PTGER3, IL23R | PTGER4 1/4885 |
| US-20170360764-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885 |
| US-20040192767-A1 | EP4 receptor antagonists | PTGER4, PTGER1, NR4A1 | PTGER4 1/4885 |
| US-20180193324-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | PTGER4, PTGER1, EPB41 | PTGER4 1/4885 |
| US-20160317514-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885 |
| US-20130225609-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS | PTGER4, PTGER1, PDE4A | PTGER4 1/4885 |
| US-20200069686-A1 | N-SUBSTITUTED INDOLE DERIVATIVES | PTGER2, PTGER1, PTGDR2 | PTGER4 7/4885 |
| US-20070123575-A1 | EP4 RECEPTOR ANTAGONISTS | PTGER4, NR4A1, PTGER1 | PTGER4 1/4885 |
| US-20170008903-A9 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | CBS, CYSLTR1, DHPS | PTGER4 192/4885 |
| US-20150148322-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | CBS, SQOR, TST | PTGER4 306/4885 |
| US-20130237527-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885 |
| US-20080039502-A1 | EP4 receptor antagonists | PTGER4, NR4A1, PTGER1 | PTGER4 1/4885 |
| US-20150045376-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | CBS, CYSLTR1, DHPS | PTGER4 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.